Human papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera.
INTRODUCTION
Human papillomavirus type 16 (HPV16) is recognized as a cause of virtually all cervical cancers and of a substantial proportion of other anogenital cancers and oropharyngeal cancers. 1 The association between HPV16 and cancers of the oral cavity and larynx is less clear but, if associated, the attributable proportion is small. 1 HPV16 has been associated with a rapid increase in the incidence of oropharynx cancer in some parts of the world, notably in the United States, Sweden, and Australia, where it is now responsible for more than 50% of cases.
2-4 If current trends continue, the annual number of oropharyngeal cancers in the United States may soon surpass the number of cervical cancers.
2
The only evidence for the temporal relationship between HPV exposure and development of head and neck cancers (HNC) comes from a study within the Nordic serum banks linked to tumor registries: a significant 14-fold increased risk for cancer of the oropharynx was reported for seropositivity to the L1 capsid protein of HPV16. 5 Antibodies against HPV L1 represent cumulative past HPV infection from multiple possible anatomic sites (ie, genital, anal, or oral), are common in controls, and do not imply the presence of a HPV-related tumor. 6 Conversely, antibody markers against HPV E6 and E7 oncoproteins should occur in response to an underlying HPV-driven neoplastic process and would be expected at low levels among cancer-free individuals. Multiple case-control studies have validated this hypothesis for HPV16 E6 seropositivity, which was present in less than 1% of controls, but not for HPV16 E7 seropositivity, which was present in 2% to 4% of controls. [7] [8] [9] [10] [11] The presence of HPV16 E7 antibody reactivity among controls is currently not understood.
We investigated antibodies against the HPV oncogenes E6 and E7, other viral regulatory proteins (E1, E2, and E4), and the L1 antigen for multiple HPV types in prediagnostic plasma from patients with HNC and matched control participants from the European Prospective Investigation Into Cancer and Nutrition (EPIC) study, a cohort of more than 500,000 adults in 10 European countries.
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METHODS
Study Cohort
EPIC procedures have been previously described in detail. 12 In brief, 521,330 individuals were recruited to the cohort between 1992 and 2000 from 10 European countries, of whom 385,747 participants contributed a blood sample. Blood fractions were aliquoted into 0.5 mL straws, which were heatsealed and stored in liquid nitrogen tanks at Ϫ196°C, except in Umeå, Sweden, where samples were stored in 1.8 mL plastic tubes in freezers at Ϫ80°C. Participants completed self-administered questionnaires on lifestyle factors and diet. All participants gave written, informed consent and the research was approved by the local ethics committees and the International Agency for Research on Cancer Ethics Committee.
Follow-Up for Cancer Incidence and Mortality Data
Incident patients with cancer were identified at regular intervals through population-based cancer registries (in Denmark, Italy except Naples, the Netherlands, Norway, Spain, Sweden, and the United Kingdom) or by active follow-up (France, Germany, Greece, and Naples), which involved a combination of methods, including a review of health insurance records, cancer and pathology registries, and direct contact with participants and their next-of-kin.
Mortality data, including vital status, cause of death, and date of death, were obtained from mortality registries at the regional or national level. Participants underwent follow-up from study entry until cancer diagnosis (except for diagnoses of nonmelanoma skin cancer), death, emigration, or the end of the follow-up period for the relevant study center. End of follow-up was defined as the latest date of complete follow-up for both cancer incidence and vital status and varied between study centers from December 2004 to June 2010. Over 98% of vital status follow-up is complete.
Selection of Patients With Cancer and Control Participants
After blood collection, 1,292 incident patients with HNC and esophagus cancer were identified according to the International Classification of Diseases for Oncology, Second Edition (ICD-O-2). The diagnoses included cancers of the oral cavity (ICD C02.0-C02.9, C04.0-C04.9, C03.0-C03.9, C05.0-C06.9, C14.0-C14.9), oropharynx (C01.9, C02.4, C09.0-C10.9), nasopharynx (C11.0-C11.9), hypopharynx (C13.0-C13.9), larynx (C32.0-C32.9), and esophagus (C15.0-C15.9). We excluded patients with a history of another cancer (n ϭ 158, except for nonmelanoma skin cancer), who did not donate a blood sample (n ϭ 152), and who were not histologically confirmed, were prevalent at the time of blood donation, or did not have questionnaire information available (n ϭ 22), leaving a total of 960 eligible patients. All histologic subtypes of HNC (84.2% of which were squamous cell carcinoma) and esophagus cancer (45.7% of which were squamous cell carcinoma) were included.
Two control participants (one in Denmark) were randomly assigned for each patient with cancer from appropriate risk sets consisting of all cohort participants alive and free of cancer (except nonmelanoma skin cancer) at the time of diagnosis (and hence, age) of the index case. Matching criteria were: country, sex, date of blood collection (Ϯ 1 month, relaxed to Ϯ 5 months for sets without available controls), and date of birth (Ϯ 1 year, relaxed to Ϯ 5 years for sets without available participants). Two control participants were available for 677 participants, and one control participant for 282 participants.
After excluding participants who did not have a sufficient volume of plasma available for antibody analysis, the final study population included 938 patients with cancer and 1,599 control participants.
Serologic Analyses
Plasma samples were sent on dry ice to the German Cancer Research Center (DKFZ, Heidelberg, Germany) and testing was performed using multiplex assays by laboratory staff who were blinded to the patient-control status of the participants. [7] [8] [9] 11 Antigens were affinity-purified, bacterially expressed fusion proteins with N-terminal Glutathione S-transferase. Samples were analyzed for antibodies to the major capsid protein (L1), the early oncoproteins (E6, E7), and other early proteins (E1, E2, E4) of the following carcinogenic mucosal types: HPV16 and HPV18 (L1, E1, E2, E4, E6, and E7); HPV31, HPV33, HPV45, and HPV52 (L1, E6, and E7); and of the noncarcinogenic mucosal types HPV6 and HPV11 (L1, E6, and E7). Mean fluorescence intensity (MFI) values were dichotomized as antibody positive or negative, 8-11 using predefined cutoff values (Appendix Table A1 [online only]) based on the mean Ϯ 5 standard deviations (SD; for HPV early proteins) or the mean Ϯ 3 SDs excluding positive outliers (for HPV late proteins) of the MFI values derived from serum samples of 117 female, HPV DNA-negative, self-reported virgins from a cross-sectional study among Korean students. 13 Values below 200 MFI were set to this minimum cutoff. For HPV6 E6, HPV11 L1, and HPV33 E7, an arbitrarily defined cutoff of 500 MFI was used.
We evaluated the reproducibility of HPV seropositivity among 114 samples that were randomly chosen at 5% within the current study population, as well as a parallel study on a different cancer site. This involved a total of 69 men and 45 women ages 34 to 77 years at recruitment. The intra-individual correlation coefficient of seropositivity for each antigen was acceptable, including for all HPV16-related proteins (L1, 0.78; E1, 0.86; E2, 0.72; E4, 0.87; E6, 1.0; E7, 0.83). A reference sample with known reactivity to three antigens (HPV16 L1, HPV16 E6, and HPV16 E7) was included on each plate as a measurement standard. Intra-individual correlation coefficients for all evaluated antigens are listed in Appendix Table A1 .
Statistical Analyses
Characteristics of the patients with cancer (overall and by anatomic site of the cancer) and control participants were evaluated. Odds ratios (ORs) and 95% CIs were calculated by anatomic site using logistic regression for seropositivity by HPV type and protein. Because few control participants were seropositive for some markers, the final risk analysis was conducted using unconditional logistic regression including all 1,599 control participants to allow calculation of OR. Covariates included in the models comprised matching factors (country, sex, and age), smoking status (never/former/current), and alcohol intake (never/ever plus alcohol g/d intake at recruitment).
All-cause mortality between HPV16 E6 seropositive and seronegative patients with oropharyngeal cancer was evaluated by Cox proportional hazards regression analysis using years since diagnosis as the time variable. The hazard ratio (HR) for HPV16 E6 seropositivity was calculated after adjustment for age at oropharyngeal cancer diagnosis, sex, and country.
To provide estimates of the 10-year cumulative incidence of oropharyngeal cancer, age-specific incidence rates by sex and smoking status (never/ former/current) were calculated using data from the entire EPIC cohort 14 and were standardized to EPIC participants ages 50 to 70 years by smoking status and sex (age-standardized rates [ASR]), as the rates were relatively stable in these age categories. These ASRs were multiplied by the smoking-specific ORs for HPV16 E6 and converted to 10-year cumulative incidence estimates.
cancers, and 1,599 cancer-free control participants. Median age at enrollment was 56.6 years, median age at cancer diagnosis was 62.8 years among patients with HNC, and their median time between blood draw and diagnosis was 6.3 years.
HPV Seropositivity and Cancer Risk
Seropositivity against HPV16 E6, one of the two HPV oncogenes that are preferentially retained and expressed in cancers, was present in prediagnostic plasma of 34.8% of patients with oropharyngeal cancer (n ϭ 47) and 0.6% of control participants (n ϭ 9; adjusted OR, 274; 95% CI, 110 to 681; Table 2 ). An increased risk was also observed for HPV16 E7 seropositivity and oropharyngeal cancer (OR, 2.4; 95% CI, 1.5 to 3.9), but the antibody was present in a substantial proportion of control participants (11%; n ϭ 178), thus reducing the estimated OR. Risk of oropharynx cancer was elevated for HPV16 L1 (OR, 3.1; 95% CI, 2.1 to 4.5), E1 (OR, 5.7; 95% CI, 3.2 to 10.0), and E2 (OR, 9.5; 95% CI, 5.7 to 15.8), but not E4.
Among patients with HPV16 E6 seropositive oropharyngeal cancer (47 of 135 participants), 42.6% (n ϭ 20) were also seropositive for HPV16 E7. None of the control participants or patients with oral cavity or esophageal cancer were seropositive for both HPV16 E6 and E7, but one patient with laryngeal cancer was dual positive for HPV16 E6 and E7.
No elevation in risk of oral cavity, larynx, or esophagus cancer was observed in relation to HPV16 antibodies except for HPV16 E1, with a significant two-fold increase in the risk of oral cavity and larynx Abbreviations: BMI, body mass index; HNC, head and neck cancer. ‫ء‬ HNC included 180 cancers of the mouth (including oral cavity, n ϭ 96; tongue, n ϭ 52; floor of mouth, n ϭ 32), 135 oropharynx cancers (tonsil, n ϭ 82; base of tongue, n ϭ 16; other oropharynx, n ϭ 37), 247 larynx cancers (including hypopharynx, n ϭ 31), 17 sinus cancers, 26 nasopharynx cancers, and 33 other HNCs (mainly overlapping sites).
†Self-reported smoking and drinking status at baseline. Columns do not add to 100% because of missing data. ‡Light drinkers were defined among men as those who consumed up to 60 gm/day and among women as those who consumed up to 30 gm/day; heavy drinkers were defined at those individuals who exceeded those thresholds.
HPV Antibodies and Risk of Subsequent Head and Neck Cancer
www.jco.org NOTE. All ORs were adjusted for sex, age at enrollment (in 5-year age categories), country, tobacco (never, former, current), and alcohol use (never/ever and continuous values in gm/day at recruitment). Abbreviations: HPV, human papillomavirus; OR, odds ratio.
cancer (Table 2) . Risk of nasopharyngeal cancer was significantly elevated for HPV16 E6 seropositivity (two [7. 7%] of 26 were positive; OR, 20.9; 95% CI, 3.4 to 128.4). Both HPV16 E6 seropositive patients with nasopharynx cancer were also positive for HPV16 E7. OR for cancer associated with non-HPV16 carcinogenic genotypes was evaluated among patients and control participants who were HPV16 seronegative because of the concern over cross-reactivity. Only HPV-33 E6 significantly elevated the risk of larynx cancer (Appendix Table A2 ); no other mucosal (Appendix Table A2 ) or cutaneous (data not shown) HPV types were associated with risk.
Stratified Analysis of HPV16 E6 Seropositivity and Oropharyngeal Cancer
HPV16 E6 seropositivity and oropharyngeal cancer were further evaluated in four strata defined by lead-time between blood collection and cancer diagnosis (Ͻ 2 years, 2 to 5 years, 5 to 10 years, and Ն 10 years; Fig 1) . HPV16 E6 seropositivity was common among patients in all lead-time categories, ranging from a minimum of 22.7% (n ϭ 5; patients with a lead time less than 2 years) to a maximum of 43.8% (n ϭ 14; patients with a lead time between 2 and 5 years; P for difference between categories was .81). Corresponding ORs were statistically significant in all lead-time categories, ranging from 218 (95% CI, 50 to 956), for cancer with a lead time of less than 2 years, and 231 (95% CI, 64 to 832), for cancer with a lead time of more than 10 years (P for trend across time categories was .89). The maximum lag time for an HPV16 E6 seropositive patient was 13.7 years.
HPV16 E6 seropositive patients with oropharyngeal cancer were more likely to be never-smokers (42.6%; n ϭ 20; Appendix Table A3 , online only) compared with HPV16 E6 seronegative patients with oropharyngeal cancer (15.9%; n ϭ 14; P Յ .001) and thus were more similar to control participants in this instance (39.5%; n ϭ 631). HPV16 E6 seropositive patients with oropharyngeal cancer also had greater body mass index (P ϭ .005) and were older at the time of diagnosis (P ϭ .03). HPV16 E6 seropositive and seronegative patients with oropharyngeal cancer were similar by sex (P ϭ 1.00), calendar year of diagnosis (P ϭ .80), region of Europe (P ϭ .75), and alcohol drinking (P ϭ .33).
All-Cause Mortality Among Oropharyngeal Cancer Participants by HPV16 E6 Seropositivity
Among patients with oropharyngeal cancer, the 5-year survival rates were 58% for those who were HPV16 E6 seronegative and 84% for those who were seropositive (Fig 2) . The HR for HPV16 E6 seropositive patients was 0.30 (95% CI, 0.13 to 0.67; P ϭ .003); further adjustment by smoking status did not affect this result (HR, 0.32; 95% CI, 0.14 to 0.73; P ϭ .007). Individual-level data on treatment or other clinical prognostic factors including stage were not available for all patients and we were unable to further account for these variables.
Cumulative Incidence of Oropharyngeal Cancer by HPV16 E6 Seropositivity
The ASR of oropharyngeal cancer within EPIC, standardized to the EPIC cohort ages 50 to 70 years, was, among men, 4.5 per 100,000 person-years among never-smokers, 8.8 among former-smokers, and 14.6 among current-smokers. The corresponding incidence rates for women were 1.3, 2.1, and 5.8 per 100,000 person-years. ORs for HPV16 E6 positivity were 596 among never-smokers (95% CI, 137 to Ͼ 1,000), 247 among former-smokers (95% CI, 67.8 to 902), and 39.7 among current-smokers (95% CI, 6.5 to 244). Among HPV16 E6 seropositive participants, the highest 10-year cumulative incidence for oropharyngeal cancer was estimated for men who were neversmokers (23.3%; 95% CI, 5.9% to 35.9%) and was lowest among female current-smokers (2.3%; 95% CI, 0.38% to 13.2%; Table 3 ).
DISCUSSION
HPV16 E6 seropositivity was present in 35% of patients with oropharyngeal cancer, in plasma specimens collected on average 6 
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Case-control studies that obtain blood samples at the time of diagnosis indicate that HPV16 E6 and E7 seropositivity are strongly associated with cancers of the oropharynx, 9 ,10,15-17 the penis, 18 and the uterine cervix. 19, 20 In cervical cancer development, HPV E6 and E7 antibodies are late tumor markers that increase with clinical tumor stage. [19] [20] [21] In a prospective study of cervical cancer (follow-up time range, 1 to 20 years), fewer than 10% of patients showed antibodies to E6 and E7 proteins of HPV16 or HPV18, compared with approximately 1% of control participants, and an association with risk was only observed for cervical cancer diagnosed within 3.5 years of blood draw. 22 Other antibodies in the HPV16 proteome, specifically HPV E1 and E2, were also elevated in patients with oropharyngeal cancer in our study, a result previously noted in a case series of HPV16 DNA-positive patients with oropharyngeal cancer.
23
HPV16 E6 seropositivity in the current prospective EPIC study was present more than 10 years before diagnosis of oropharynx cancer. Given that this was the longest interval analyzed for this cohort, the true lead time may be longer. It is unclear at what point the HPV16 E6 antibodies are generated and are detectable, be it a clinically important persistent oral HPV infection, an HPV-driven intraepithelial neoplasia (ie, a precursor lesion or preinvasive disease), or a slowly developing carcinoma. The fact that tonsils are lymphoid organs and rich in antigen-presenting cells may contribute to the relatively long time between seroconversion and cancer diagnosis, making this finding specific to the oropharynx and theoretically unlike other HPVassociated cancer sites. Specifically, immune presentation of infections at the tonsil/oropharynx may induce HPV16 E6 seroconversion in the absence of invasive disease.
The estimated 10-year risks of oropharyngeal cancer within EPIC were 7% and 23% for HPV16 E6-seropositive female and male neversmokers, respectively, though they were associated with wide CIs, and more accurate evaluations in larger studies are warranted. These estimates are comparable with the risk stratification achieved for HPV DNA testing in cervical cancer, for which the 10-year likelihood of developing cervical precancer among HPV16 DNApositive women age older than 30 years was 17%. 24 The finding that the 10-year risk for HPV16 E6 seropositivity was higher among never-smokers than among current smokers is consistent with previous case-control studies, showing a strong negative interaction with HPV serology and tobacco smoking.
17, 25 Development of oropharyngeal cancer may be driven by the carcinogenic effects of either tobacco-or HPV-induced genomic instability. As such, smokers may not need the HPV16-infection-induced pathway to cancer whereas nonsmokers do.
Our study raises several questions. First, the proportion of HPV16 E6 seropositive participants who were HPV16 DNA-positive in the tumor tissue is unknown, although efforts are currently underway to identify tumor blocks from a sample of the patients. Yet, the HPV16 E6 seropositive patients with oropharyngeal cancer were more likely to be never-smokers and have a better prognosis, as found in previous studies of HPV16 DNA-positive patients with oropharyngeal cancer, 26 thereby making it likely that most of the serologically detected oropharyngeal cancers were HPV16 DNA-positive as well. While the sensitivity of the HPV16 E6 antibody assay for detection of HPV16 DNA-driven oropharyngeal cancer is currently unknown, the capacity to detect oropharyngeal cancer overall could be higher in regions such as the United States where 70% of contemporaneous oropharyngeal tumors are thought to be caused by HPV infection. Second, further quantification of the lead time between HPV16 E6 seroconversion and cancer detection is warranted, to better understand how far in advance testing could occur. Analysis of repeat samples will also help determine the robustness of the serologic response. Third, of the nine HPV16 E6 seropositive control participants (of 1,599), we noted with interest that one developed anal cancer during the study period. This raises the question of whether the HPV16 E6 seropositivity rate among control participants in this study (0.6%) indicates the assay's false-positive rate, or if these controls may be at increased risk of eventually developing HPV-associated cancer (or a combination of the two). And finally, it will be important to more precisely evaluate the interaction between HPV16 E6 and smoking status, although a larger collaborative effort involving multiple prospective cohorts would seem necessary to obtain an adequate sample size. NOTE. All ORs were adjusted for sex, age at enrollment (in 5-year age categories), country, tobacco (never, former, current), and alcohol use (never/ever and continuous values in gm/day at recruitment). The larynx cancer category includes 31 patients with hypopharyngeal cancer. Abbreviations: HPV, human papillomavirus; OR, odds ratio.
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